tiprankstipranks
VALN’s Chikungunya Vaccine Bags Priority Review
Market News

VALN’s Chikungunya Vaccine Bags Priority Review

Specialty vaccine maker Valneva SE’s (NASDAQ:VALN) biologics license application for its single-shot chikungunya vaccine candidate VLA1553 has received a priority review from the U.S. Food and Drug Administration.

Next, the prescription drug user fee act (PDUFA) date for the review has now been set for the end of August this year.

At present, there are no effective treatments or preventive vaccines for chikungunya on the market and over 75% of the global population currently resides in areas with a risk of chikungunya transmission.

Overall, Wall Street has a consensus price target of $25 on VALN, implying a whopping 97% potential upside in the stock. That’s after a nearly 60% side in the share price over the past 52 weeks.

Read full Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
VALN’s Chikungunya Vaccine Bags Priority Review
News On DemandStay up-to-date on market-moving news with a feed made just for youGet the App

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
RUT
Russell 2000
TNX
10-Yr-Bond
Bitcoin

Popular Articles